NZ269335A - Purine and analogues substituted in position-9 by dioxabicyclic and carbobicyclic moieties - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £69335 New Zealand No. 269335 International No.

TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 23.07.1993; Complete Specification Filed: 24.06.1994 Classification:^) C07D473/32.36; C07D519/00; C07D471/04; A61K31/52 Publication date: 19 December 1997 Journal No.: 1423 no DRAWINGS NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: Novel 9-N-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines Name, address and nationality of applicant(s) as in international application form: MERRELL PHARMACEUTICALS INC., a company organised under the laws of the United States of America of 2110 East Galbraith Road, Cincinnati, Ohio 45215-6300, United States of America WO 95/03304 PCT/US94/07147 26933 5 NOVEL 9-N-BICYCLIC NUCLEOSIDE AGENTS USEFUL AS SELECTIVE INHIBITORS OF PROINFLAMMATORY CYTOKINES BACKGROUND OF THE INVENTION Autoimmune and inflammatory diseases affect more than 10 fifty million Americans. As a result of basic research in molecular and cellular immunology over the last ten to fifteen years, approaches to diagnosing, treating and preventing these immunological based diseases has been changed forever. By dissecting the individual components 15 of the immune system, those cells, receptors and mediators which are critical to the initiation and progression of immune responses have been, and continue to be, elucidated. Crystallographic analysis of proteins encoded in the major histocompatability complex, identification of an antigen-20 specific T cell receptor, and development of a basic understanding of the complex cytokine network have all contributed to a revolution in immunology. Equipped with this new and fundamental information about basic immune mechanisms, selective and - ional approaches to the 25 treatment of inflammatory and autoimmune disease can now be developed.

Until the last decade, treatment of immunological based disorders were treated exclusively with nonspecific 30 immunosuppressive agents. These included a variety of drugs, such as corticosteroids, antimalarials, methotrexate, azathioprine, and treatments such as total lymphoid irradiation. Although some of these approaches may affect one component of the immune response more than another, they remain nonspecific in their actions and * treatment frequently is complicated by serious side effects. It would be very useful to discover and develop new drugs which are immune cell selective or mediator specific awd which interfere wi \;h processes critical to the initiation, progression, and maintenance of the acute and chronic inflammatory processes associated with certain 5 immunological based diseases.

The two most important cells of the immune response in the autoimmune and inflammatory processes are the T lymphocyte and the monocyte/macrophage.

The T cell is critical to all antigen driven cellular immune responses. There are at least two major subpopulations of T cells: T helper (CD4+) and T cytotoxic (CD8+). T cells recognize antigen via a unique membrane 15 receptor: the T cell antigen receptor (TCR). The TCR can recogni2e antigen only in association with cell surface proteins known as major histocompatibility complex (MHC) molecules. In response to antigen presented by MHC class. II molecules, T helper cells secrete a variety of soluble 20 factors, collectively known as lymphokines. Lymphokines play an essential role .in the activation, differentiation, and expansion of all the cells of the immune response. In contrast to the T helper cell, the T cytotoxic cell responds to antigen in the context of MHC class I 25 molecules. Cytotoxic T lymphocytes, once activated, can eliminate cells displaying a specific antigen derived from a virus, tumor cell, or foreign tissue graft.

Mononuclear phagocytic macrophages are widely 30 distributed throughout the body and display great structural and functional heterogeneity. Macrophages are derived from circulating monocytes which migrate into extravascular tissues. The migration of peripheral blood monocytes involves adherence to the endothelium, migration 35 between endothelial cells, and subsequently movement through subendothelial structures. Adherence of monocytes to endothelium involves high molecular weight glycoproteins, such as lymphocyte function-associates antigen 1 (LFA-1; CDlla/CD18), which interacts with intercellular adhesion molecule-1 (ICAM-1; CD54) present on vascular endothelial cells. Monocytes and macrophages 5 produce a variety of pro-inflammatory mediators (cytokines), such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF). These cytokines have numerous effects on many cells within and outside the immune system, such as promoting activation, 10 differentiation, expansion, or apoptosis. In addition, cytokines such as IL-1 increase the expression of adhesion molecules like ICAM-1 and greatly facilitate monocyte migration to the inflammatory site. Furthermore, the monocyte/macrophage is one of the major types of antigen 15 presenting cells required for T helper cell activation.

During the last decade, an understanding of immunopathological reactions has greatly evolved as a result of the characterization of cytokines and interleukins which 20 regulate interactions between cells of the immune system and other nonimmune tissues and cells such as endothelial cells, fibroblasts and adipocytes. A major cytokine increasingly recognized as a central mediator in a wide spectrum of physiologic and immune functions is macrophage-derived Tumor 25 Necrosis Factor-a, also known as TNF-a, or Cachectin. TNF-a has been found to mediate effects as diverse as tuinoricidal activity, wasting and weight loss associated with chronic disease, promotion of cartilage erosion and the destruction of joints in rheumatoid arthritis, and the recruitment of 30 cells to participate more effectively in the host's response to an invasive agent. In addition, an increasingly large body of evidence indicates that TNF-a serves as the proximal mediator in the evolution of septic shock.

The biological function of TNF-a extends well beyond its initial discovery as a mediator of tumor necrosis. It is increasingly realized that the interacting milieu of host cytokines existing locally and systemically is an extremely important network that dictates the pathogenesis of many immune and inflammatory diseases. TNF-a appears to play a critically important role in this regard because of its 5 ability to activate a wide range of cell types in order to promote production of several key cytokines (e.g. IL-18, IL-la and IL-6), bioactive eicosanoids, and platelet activating factor (PAF).

Enhanced synthesis and release of cytokines has been observed during many acute and chronic inflammatory processes, and it is increasingly realized that in many cases, overproduction of TNF-a is a major contributor to inflammation, cellular injury, and cell death associated 15 with various immunological based diseases.

There is now evidence to indicate that TNF-a is a primary mediator of septic shock. TNF-a, along with other cytokines, triggers inflammatory and metabolic responses 20 attributed to sepsis and septic shock including adult respiratory distress syndrome (ARDS), fever, and disseminated intravascular coagulation. ARDS is characterized by increased pulmonary capillary permeability resulting in noncardiogenic pulmonary edema, decreased lung 25 compliance and decreased lung volume. Although ARDS is frequently associated with sepsis, it also occurs as a result of smoke inhalation, pancreatitis and long-bone fractures.

Patients infected with the human immunodeficiency virus (HIV) enter a long period of clinical latency prior to developing clinically apparent disease. HIV infects T cells as well as monocytes and macrophages, and activation of latent or marginally active HIV infected cells may be 35 promoted in part by cytokines, including TNF-a. TNF-a has also been implicated in the pathogenesis of fever, cachexia (wasting syndrome), and Myobacterium tuberculosis infections in patients with acquired immunodeficiency syndrome (AIDS).

Cytokines, including TNF-a, are known to play an 5 important role in the pathogenic processes of inflammatory bowel disease. Ulcerative colitis and Crohn's disease are two common forms of inflammatory bowel disease.

Complex patterns of interacting cytokines, including 10 TNF-a, and products of arachidonic acid metabolism produced locally in' the central nervous system have been implicated in contributing to adverse sequelae of bacterial meningitis.

Rheumatoid arthritis is a heterogenous, systemic disease 15 of unknown etiology, and persons with rheumatoid arthritis typically develop inflammation of joint synovium (synovitis). Clinical symptoms become apparent with progression of synovitis due to production and release of cytokines from activated macrophages along with activation 20 of T lymphocytes, angiogenesis, and attraction of neutrophils to the joint cavities. Cytokines induce synovial cell proliferation, resulting in invasion and destruction of articular cartilage. Synovial fibroblasts are thought to become activated by proinflammatory mediators 25 such as TNF-a to secrete a large variety of cytokines and growth factors. TNF-a activity in rheumatoid arthritis includes recruitment and activation of PMNL leukocytes, cellular proliferation, increased prostaglandin and matrix-degrading protease activity, fever, and bone and cartilage 30 resorption. TNF-a and TNF-a-induced IL-1 induce synthesis of collagenase and stromelysin by synoviocytes, contributing to loss of normal joint integrity and function.

Other diseases/syndromes in which TNF-a is implicated 35 are vascular injury/atherosclerosis, diabetes mellitus type I, Kawasaki disease, leprosy, multiple sclerosis, anemia of chronic disease, ultraviolet radiation, Helicobacter pylori PCT /US94/07147 gastritis/ulcer disease, paracoccidioidomycosis, septic melioidosis) heart failure, familial Mediterranean fever, toxic shock syndrome, chronic fatigue syndrome, allograft rejection, Graft-versus-host disease, Schistosomiasis.

Thus, it would be very useful to provide a means for inhibition of TNF-a activity in a variety of disease states. The present invention now provides a means for inhibition of TNF-a activity. This provides a treatment for patients 10 suffering from acute and chronic inflammatory processes associated with various immunological based diseases including septic shock, ABDS, inflammatory bowel disease including ulcerative colitis and Chrohn's disease, bacterial meningitis, rheumatoid arthritis, fever/cachexia (wasting 15 syndrome)/Myobacterium tuberculosis infections in patients with AIDS, vascular injury/atherosclerosis, diabetes mellitus type 1, Kawasaki disease, leprosy, multiple sclerosis, anemia of chronic disease, ultraviolet radiation, Helicobacter pylori gastritis/ulcer disease, paracoccidioidomycosis, septic 20 melioidosis, heart failure, familial Mediterranean fever, toxic shock syndrome, chronic fatigue syndrome, allograft rejection, Graft-versus-host disease, Schistosomiasis. In addition, the present invention provides a treatment which inhibits the activation of latent or marginally active HIV 25 infected cells in patients with AIDS.

M01698 5UMMARY OF THE INVENTION The present invention provides compounds having the 5 following general formula (I): Z, formula (I) wherein 15 Y is nitrogen or CH; and Z2 are each independently hydrogen, halogen or NH2; and A is selected from the group consisting of: wherein Xi, X2 and X3 are each' independently hydrogen, OH, N3, NH2, N{R)2, NHR, CN, CH2NH2, CONH2, C02H, CH2OH, SH or SR wherein R is Cj-C4 alk.y-1; and 35 the pharmaceutical^ acceptable salts thereof; with the proviso that at least one of Xi, X2 or X3 is other than hydrogen; - ' .

AMFNDED sheet M0I693 •7/1- 269 335 ana with the further proviso that when Zi is nh^ ; Z2 is H or NH2; A is X3 is H or OH; X2 is E; then Xi is not C02H , and with the further proviso that when Z2 is H ; 1 is Xi is C02H, then 2i is other than a halogen.

N.2. PATENT OFFICE OCT 199? The present invention further provides compounds having the following general formula: ?i formula (II) wherein Y is nitrogen or CH; Z2 and Z2 are each independently hydrogen, halogen or NH2' and X is N3, m2, N(R)2, NHR, CN, CH2NH2, CONH2, C02H, CH2OH, 20 SH or SR; wherein R is CX-CA alkyl; and the pharmaceutically acceptable salts thereof. -6^335 In our related New Zealand Patent Specification No. 328982 there is claimed a method of inhibiting the TNF-a activity in a patient in need thereof comprising administering to said patient an effective 5 antiinflammatory amount of a compound of formulas (I) or (II) or of formula (III); Zi formula (III) wherein 20 ¥ is nitrogen or CH; Z2 and Z2 are each independently hydrogen, halogen or NH2; and the pharmaceutically acceptable salts thereof.

New Zealand Patent Specification No. 328982 also 25 claims a method of treating a patient suffering from septic shock comprising administering to said patient an effective immunosuppressant amount of a compound of formulas (I), (II) or (III).

The present invention also provides use of a compound of formulas (I) or (II) for the preparation of a medicament for the inhibition of Tumor Necrosis Factor alpha.

The present invention further provides use of a compound of 35 formulas (I) or (II) for the preparation of a medicament for the treatment of septic shock.

N.Z. PATENT OCT 1S97 RECEIVED 26 3 3 3 5 In addition/ the present invention provides for use of a compound of formulas (I) or (II) for the preparation of a medicament for inhibiting Tumor Necrosis Factor alpha in a patient in need suffering from septic shock comprising administering to the patient an amount of a compound of formulas (I) or (II).

The present invention also provides use of a compound for the preparation of a medicament for inhibiting Tumor Necrosis Factor alpha in a patient suffering from septic shock comprising administering to the patient an amount of a compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclo(3,3,0Joctane dihydrochloride, (+)-exo- 2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane, (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1, 6-diol,, (+ )-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1,6-diol dihydrochloride, (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, (+)-exo-3-(6-amino-pur in-9-yl)-octahydropentalene-diendo-2, 4-diol dihyrochloride, [3S, 6R)-6-(6-amino-purin-9-yl)-hexahydrb-furo(3,2-b]furan-3-ol, [3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-£uro[3,2-b]furan-3-ol dihydrochloride, [3Rf 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol, or (3R, 6R ]-6- ( 6-amino-pur i'n-9-yl) -hexahydro-furo [ 3,2-b] f u.ran- 3-ol dihydrochloride.

The present invention further provides use of a compound for the preparation of a medicament for the inhibition of Tumor Necrosis Factor alpha, wherein the compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane dihydrochloride, (+)-exo-2-adenyl-endo-6-hydroxybicyclo(3,3,0]octane, (+)-exo-5-{6-amino-purin-9-yl)^octahydropentalene-diendo-1,6-diol, (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1,6-diol dihydrochloride, (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, (+)-exo-3—(6-amino- pu rin-9-yl ) -octahydr open talene-diendo-2 ,4-diol dihyrochloride, [3S, 6R]-6-(6-amino-purin-9-2F OCT w (followed by page -9b-) RECEIVED -9b- 269 33 5 furo[ 3, 2—b]furan-3-ol, [3S, 6R]-6-( 6-ami'no-purin-9-yl) -hexahydro-furo[3,2-b]furan-3-ol dihydrochloride, (3R, 6RJ-6-(6-amino-pur in-9-yl)-hexahydro-furo[3,2-b]furan-3-ol, or [ 3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2—b]furan-3-ol dihydrochloride.

Additionally/ the present invention provides use of a compound for the preparation of a medicament for the treatment of septic shock, wherein the compound is (+)-exo-2-adenyl-endo-6- hydroxybicyclo[3,3,0]octane dihydrochloride, (+)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane, (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1,6-diol, (+) -exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1,6-diol dihydrochloride, (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, (+)-exo-3-(6-amino-pur iri-9-yl)-octahydropentalene-diendo-2,4-diol dihyrochloride, [3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro.-furo[3,2-b]furan-3-ol, [3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol dihydrochloride, [3R, 6R]—6— (6-amino-purin-9-yl)-hexahydro-furo(3,2-b]furan-3-ol, or [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol dihydrochloride.

The present invention also provides for a pharmaceutical composition comprising an effective immunosuppressive amount of a compound of Formula (I) or (II) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

N.Z. PATENT OFF,' 2 0 Oi l b'bV RECEIVED (followed by page -10-) DETAILED DESCRIPTION OF THE INVENTION As used herein the term "Cj-^ alkyl" refers to a saturated straight or branched chain hydrocarbon radical of 5 one to four carbon atoms. Included within the scope of this term are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and the like. The term "halogen" or "halo" refers to a chlorine, bromine or iodine atom. The term "Pg" refers to a protecting group such as 10 isopropyldimethylsilyl, tert-butyldiphenylsilyl, methyl-di-tert-butylsilyl, tert-butyldimethylsilyl, benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-chlorobenzyl, triphenylmethyl, methoxymethyl, 2-methoxyethoxymethyl, acetate and benzoate. The term "Lg" 15 refers to a leaving group such as methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, 2-nitrobenzenesulfonate, 3-nitrobenzenesulfonate, 4-nitrobenzenesulfonate or 4-bromobezenesulfonate and the like. It is understood in the art that a protecting group 20 can function as a leaving group and a leaving group can function as a protecting group depending upon the reaction conditions utilized.

The terms "Ms" or "mesylate" refers to a 25 methanesulfonate functionality of the formula: O O \ The terms "Ts" or "tosylate" refers to a p-toluenesufonate functionality of the formula; The term "pharmaceutically acceptable salt" refers to those salts that are not substantially toxic at the dosage 20 administered to achieve the desired effect and do not independently possess significant pharmacological activity. The salts included within the scope of this term are hydrobromide, hydrochloride, sulfuric, phosphoric, nitric, formic, acetic, propionic, succinic, glycolic, lactic, 25 malic, tartaric, citric, ascorbic, a-ketoglutaric, glutamic, aspartic, maleic, hydroxymaieic, pyruvic, phenylacetic, benzoic, p-aminobenzoic, anthranilic, p-hydroxybenzoic, salicyclic, hydroxyethanesulfonic, ethylenesulfonic, halobenzenesulfonic, toluenesulfonic, 20 naphthalenesulfonic, methanesulfonic, sulfanilic, and the like. Hydrochloride is preferred as the pharmaceutically acceptable salt of compounds of formulas If II and III.

It is understood that these compounds of formulas (I), 25 (II) and (III) may exist in a variety of stereoisomeric configurations wherein the substituents Xi, x2 and X3 on A of formula (I), substituent X of formula (II) and the hydroxyl on formula (III) may be in the Endo or Exo configuration relative to the bicyclic ring of formula (IV) fo-mula (IV) wherein the substituents are as previously defined and A is 10 connected to the ring at the 9-position of formula (IV).

' It is further understood that the bicyclic ring compounds defined by A may exist in the CIS or TRANS configuration about the ring juncture. For example the 5-5 15 ring system may have the following configuration H H H TRANS It is further understood that where the relative 25 configuration is fixed, the maximum number of enantiomers possible for each compound is equal to 2" wherein n represents the total number of chiral centers located on the compound and can be the integer 1, 2, 3 or 4 depending upon the substitution present on the compound. These 30 stereoisomers, including the enantiomers are specifically understood to be included within the scope of the present invention.

The compounds of formula (I) wherein Xi, X2 and X3 are 35 each independently H or OH can be prepared as described in Scheme I with the proviso that at least one of Xi, X2 or X3 is other than hydrogen. All the substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art.

Scheme I Step A Coupling Reaction A'-OLg StepB Deprotection A'-OLg is a suitably protected bicyclic sulfonate derivative which is readily available to one of ordinary skill in the art. A'-OLg is selected from the group consisting of: OLg OLg Xi' Xt' Xi' OLg X2' X3' A . X , (a') (b') X2 X3 m n X2' OLg (O wherein Xi', X2' and X3( are each independently hydrogen or OPg wherein Pg is a suitable protecting group with the 25 proviso that at least one of Xi1, X2' or X3* is other than hydrogen. Examples of suitable protecting groups are isopropyldimethylsilyl, tert-butyldiphenylsilyl, methyl-di-tert-butylsilyl, tert-butyldimethylsilyl, benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-2q chlorobenzyl, triphenylmethyl, methoxymethyl, 2- methoxyethoxymethyl, acetate, benzoate and the like. The preferred protecting group is tert-butyldimethylsilyl.

In Scheme I, step A the bicyclic compound of structure 25 (1) is coupled to the suitably protected sulfonate derivative A'-OLg under conditions well known in the art.

For example, the bicyclic compound (1) is combined with a suitable solvent, such as dimethylformamide in a reaction 30 bomb and treated with an equivalent of a suitable base, such as sodium hydride. Examples of appropriately substituted bicyclic compounds (1) are adenine, 2,6-diaminopurine, 6-chloropurine, 2-amino-6-chloropurine, 3-deazoadenine and the like. Adenine is the preferred 35 bicyclic compound (1). The reaction is allowed to stir for about 1 to 3 hours at room temperature to provide the anion of bicyclic compound (1). About 0.3 to 0.4 equivalents of the suitably protected sulfonate derivative A'-OLg is added to the anion of bicyclic compound (1) in the bomb. The bomb is sealed and heated at about 150°C for about 10 to 24 hours. After cooling the product is isolated by extractive techniques well known in the art. For example the reaction 5 is rinsed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue is then purified by techniques well known in the art, such as flash chromatography on silica gel to provide the protected compound described by structure (2).

In Scheme I, step B the protecting group(s) on protected compound (2) is(are) removed under conditions veil known in the art that may vary depending upon the particular protecting group utilized to provide the desired 15 deprotected compound described by formula (I') wherein Ai is selected from the group consisting of: wherein Xi, X2 and X3 are each independently hydrogen or OH with the proviso that at least one of Xi, X2 or X3 is other 30 than hydrogen. When more than one protecting group is present on compound (2) they may be removed simultaneously or sequentially depending upon the protecting group employed, the reaction conditions utilized and the product desired by techniques well known and understood in the art 35 of chemistry.

In addition compounds of formula (I') can be prepared by treatment of cis-endo-8-hydroxy-bicyclo[3.3.0]octane- endo-2,3-oxirane with the anion of bicyclic compound (1) to provide a mixture of epoxide ring opened products (la1) and (lb') which can be separated by techniques well known in the art such as flash chromatography on silica gel.

The compounds of formulas (I) and (II) wherein X is N3, NHR, N(R)2r CN, SH or SR can be prepared as described in Scheme II. All other substituents, unless otherwise indicated, are previously defined. Starting material for preparation of compounds of formula (II) can be prepared as described in U.S. Patent No. 4,479,951, October 30, 1984 and U.S. Patent No. 4,535,158, August 13, 1985. The reagents and starting materials are readily available to one of ordinary skill in the art. formula (I•) Ai or formula (III) Scheme II Step A Leaving Group Formation StepB Nucleophilic Substitution. formula (I") or formula (II*) A3 In Scheme II, step A formula (I') or (III) are converted to compound (3) under conditions well known in the art wherein A2 is selected from the group consisting of WO 95/03304 PCT/US94/07147 wherein Xi, X2 and X3 are each independently hydrogen or OLg with the proviso that at least one of Xi, X2 or X3 is other than hydrogen. Lg is a suitable leaving group. Examples of suitable leaving groups are methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, 2-nitrobenzenesulfonate, 3-nitrobenzenesulfonate, 4-nitrobenzenesulfonate,4-bromobezenesulfonate and the like. Methanesulfonate is the preferred leaving group.

For example, the appropriately substituted compound of formulas (!') or (III) are dissolved in a suitable organic solvent mixture, such as methylene chloride and tetrahydrofuran (5:3). An excess of methanesulfonyl chloride and triethylamine is added and the reaction is stirred for 30 minutes to 3 hours. The reaction is then quenched with water and extracted with a suitable organic solvent, such as methylene chloride. The combined organic extracts are dried over a suitable drying agent, such as anhydrous sodium sulfate, filtered and concentrated under vacuum to provide the compound described by structure (3).

In Scheme II, step B the compounds described by structure (3) undergo a nucleophilic substitution reaction by treatment with a suitable nucleophile to provide the compounds described by formulas (I") and (II') wherein A3 is selected from the group consisting of: wherein Xi, X2 and X3 are ea ; independently hydrogen, ,, NHR, N(R) 21 CN or SH with t:. proviso that at least one of Xi, X2 or X3 is other than hydrogen.

For example an appropriately substituted compound (3) is dissolved in a suitable solvent. Examples of a suitable solvent are dimethylsulfoxide, dimethylformamide, ethanol and the like. The preferred solvent is ethanol. The solution is then treated with an excess of a suitable nucleophile. Examples of suitable nucleophiles include sodium azide, sodium cyanide, potassium cyanide, lithium cyanide, methylamine, dimethylamine, methyl mercaptide, sodium hydrosulfide, potassium thioacetate and the like. The reaction is stirred at room temperature for approximately 24 hours and then heated at reflux for 2 to 6 hours. Alternatively the reaction can be directly heated at reflux for 2 to 6 hours. The reaction is then concentrated under vacuum and the residue is purified by techniques well known to one skilled in the art. For example, the residue is dissolved in a suitable organic solvent mixture, such as methylene chloride:methanol (9:1) and passed through a plug of 'silica gel. The filtrate is then concentrated under vacuum to provide the appropriately substituted compound described by formulas (I") or (II1).

The compounds of the formulas (I) and (II) wherein X, Xi, X2 and X3 are each independently hydrogen, CH2NH2, C02H, CONH2 and CH2OH with the proviso that at least one of X, Xi, 5 X2 or X3 is other than hydrogen, can be prepared by one of ordinary skill in the art from the corresponding cyano substituted derivative of formulas (I") or (II1), prepared in Scheme II.

For example an appropriately substituted compound of formulas (I") or (II') wherein Xi, X2 and Xa on A3 are each independently hydrogen or CN with the proviso that at least one of Xi, X2 or X3 is other than hydrogen, is reduced to the appropriately substituted aminomethyl compound 15 utilizing techniques well known in the art.

For example, the appropriately substituted cyano compound of formulas (IM) or (II*) is dissolved in a suitable solvent, such as tetrahydrofuran and treated with 20 an excess of a suitable reducing agent, such as 2M aluminum hydride in tetrahydrofuran. The reaction is refluxed for 2 to 6 hours. Excess reducing agent is carefully decomposed by treatment with acetone and then acidified to pH 7. The mixture is then filtered and the filtrate is concentrated 25 under vacuum. The residue is purified by techniques well known to one skilled in the art. For example, the residue is purified by flash chromatography on silica gel with methylene chloridesmethanol (17:3) as eluent to provide the appropriately substituted compounds of formulas (I) and 30 (II) wherein X, Xi, X2 and X3 on A are each independently hydrogen or CH2NH2 with the proviso that at least one of X, Xi, X2 or X3 is other than hydrogen.

Additionally, an appropriately substituted compound of 35 formulas (I") or (II*) wherein Xi, X2 and X3 on A3 are each independently hydrogen or CN with the proviso that at least one of Xi, X2 or X3 is other than hydrogen, is hydrolyzed to the appropriately substituted amide derivative utilizing techniques well known in the art.

For example, the appropriately substituted cyano 5 compound of formulas (I") or (II') is dissolved in a suitable solvent, such as methanol and treated with an equivalent of a suitable base, such as potassium hydroxide. The reaction is heated at reflux for 1 to 5 hours and then concentrated under vacuum. The residue is then purified by 10 techniques well known in the art. For example the residue can be purified by flash chromatography on silica gel utilizing a suitable eluent, such as methylene chloridesmethanol to provide the appropriately substituted compounds of formulas (I) and (II) wherein X, Xi, X2 and X3 15 on A are each independently hydrogen or CONH2 with the proviso that at least one of X, Xi, X2 or X3 is other than hydrogen.

Additionally, an appropriately substituted compound of 20 formulas (IM) or (II') wherein Xi, X2 and X3 on A3 are each independently hydrogen or CN with the proviso that at least one of Xi, X2 or X3 is other than hydrogen, is hydrolyzed to the appropriately substituted carboxylic acid derivative utilizing techniques well known in the art.

For example, the appropriately substituted cyano compound of formulas (I") or (II') is dissolved in a suitable organic solvent, such as tetrahydrofuran. An excess of a suitable base, such as potassium hydroxide is 30 added and the reaction is heated at reflux for approximately 6 hours. After cooling, the reaction is neutralized with a suitable acid, such as 6N hydrochloric acid and the product purified by techniques well known to one skilled in the art. For example, the product can be 35 isolated by ion exchange chromatography to provide the appropriately substituted compounds of formulas (I) and (II) wherein X, Xi, X2 and X3 on A are each independently hydrogen or CO2H with the proviso that at least one of X, Xi, X2 or X3 is other than hydrogen.

The carboxylic acid derivative described above can then 5 be reduced under conditions well known in the art to provide the corresponding hydroxymethyl derivative.

For example, the appropriately substituted carboxylic acid is dissolved in a suitable organic solvent, such as tetrahydrofuran. An excess of a suitable reducing agent, such as 2M lithium aluminum hydride in tetrahydrofuran is added dropwise to the reaction. The reaction is heated at reflux for 2 to 6 hours. After cooling, excess reducing agent is decomposed by treatment with acetone followed by dilute hydrochloric acid to adjust to pH 7. The mixture is then filtered and the filtrate is concentrated under vacuum. The residue is then purified by techniques well known to one skilled in the art. For example, the residue can be purified by flash chromatography using methylene chloride methanol (17:3) as the eluent to provide the appropriately substituted compounds of formulas (I) and (II) wherein X, Xi, X2 and X3 on A are each independently hydrogen or CH2OH with the proviso that at least one of X, Xif X2 or X3 is other than hydrogen.

The compounds of the formulas (I) and (II) wherein X, Xi, X2 and X3 are on A are hydrogen or NH2 with the proviso that at least one of Xi, X2 or X3 is other than hydrogen, can be prepared from the corresponding azide derivative [the azide derivative is prepared by nucleophilic substitution of compound (3) with sodium azide as described generally in Scheme II, step 8].

For example, the appropriately substituted azide 35 [formulas (IH) or (II') wherein Xi, X2, and X3 are each independently hydrogen or N3 with the proviso that at least one of Xi, X2 or X3 is other than hydrogen.] is dissolved in WO 95/03304 PCT/US94/07147 a suitable organic solvent, such as tetrahydrofuran and treated with an excess of a suitable reducing agent, such as 2M lithium aluminum hydride in tetrahydrofuran. The reaction is heated at reflux for 2 to 6 hours. After 5 cooling, the excess reducing agent is decomposed with water, the mixture is filtered and the filtrate is concentrated under vacuum. The residue is then purified by techniques well known to one skilled in the art. For example, the residue is purified by flash chromatography 10 using silica gel and a suitable organic eluent, such as methylene chloride:methanol (17:3) to provide the appropriately substituted compounds of formulas (I) and (II) wherein X, Xi, X2 and X3 on A are each independently hydrogen or NH2 with the proviso that at least one of Xi, X2 15 or X3 is other than hydrogen.

More specifically the compounds of of formula (I) wherein A is an appropriately substituted octahydropentalene, Xi and X3 are hydrogen, and X2 is OH, 20 can be prepared as described in Scheme III. All the substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art.

I Scheme III OAc OH OH OH In Scheme III, step A the (+)-diendo-2,6-diacetoxybicyclo[3,3,0]octane (4) [prepared following the procedure described by Henry et al. J. Chem. Soc. Chem.

Comm. 1974, 112] is hydrolyzed to the dihydroxy derivative described by structure (5).

For example the (+)-diendo-2,6-diacetoxybicyclo[3,3,0]octane (4) is dissolved in a suitable organic solvent, such as methanol and treated with 2 equivalents of a suitable base, such as potassium hydroxide and allowed to stir at room temperature for 1 to 3 hours. The reaction is then concentrated under vacuum and the residue purified by techniques well known in the art, such as chromatography on silica gel to provide the dihydroxy derivative (5).

In step B the dihydroxy derivative (5) is monoprotected under conditions well known in the art to provide the appropriately substituted monohydroxy derivative described by structure (6).

For example the dihydroxy derivative (5) is dissolved i suitable organic solvent, such as methylene chloride. It is then treated with a catalytic amount of 4-dimethylaminopyridine, an equivalent of a suitable acid 20 scavenger, such as triethylamine and an equivalent of a suitable protecting group. Examples of suitable protecting groups are tert-butyldimethylsilyl, isopropyldimethylsilyl, methyl-di-tert-butylsilyl, tert-butyldimethylsilyl, acetate, benzoate, tetrahydropyranyl and the like. The 25 preferred protecting group is tert-butyldimethylsilyl. The reaction is allowed to stir for 10 to 24 hours at room temperature. The product is then isolated extractive methods well known in the art. For example the reaction can be washed with water, brine, dried over anhydrous 30 sodium sulfate, filtered and concentrated under vacuum. The residue is then purified by techniques well known in the art, such as flash chromatography on silica gel to provide the monohydroxy derivative (6).

^ In step C the monohydroxy derivative (6) is converted to the appropriately substituted mesylate described by structure (7) under conditions well known in the art.

For example the monohydroxy derivative (6) is dissolved in a suitable organic solvent, such as methylene chloride* It is then treated with a slight excess of methanesulfonyl 5 chloride and a slight excess of a suitable acid scavenger, such as triethylamine. The reaction is stirred for 1 to 3 hours at room temperature. The mesylate (7) is then isolated by extractive methods well known in the art. For example the reaction is washed with water, brine, dried 10 over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide the mesylate (7).

In step D the mesylate (7) is immediately coupled to the appropriately substituted anion of the bicyclic 15 compound of structure (7a) under conditions that are well known in the art to provide the appropriately substituted compound (8).

For example an appropriately substituted bicyclic 20 compound (7a) is combined with a suitable solvent, such as dimethylformamide in a reaction bomb and then treated with an equivalent of a suitable base, such as sodium hydride. Examples of bicyclic compounds (7a) are adenine, 2,6~ diaminopurine, 6-chloropurine, 2-amino-6-chloropurine, 3-25 deazoadenine and the like. The preferred bicyclic compound (7a) is adenine. The reaction is allowed to stir for about 1 to 3 hours at room temperature to provide the anion of (7a). About 0.3 to 0.4 equivalents of the mesylate (7) are added to the anion of (7a) in the bomb, the bomb is sealed 30 and heated at about 150°C for about 10 to 24 hours. After cooling the product is isolated by extractive techniques well known in the art. For example the reaction is rinsed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue is 35 then purified by techniques well known in the art, such as flash chromatography on silica gel to provide compound (8).

WO 95/03304 PCT/US94/07147 In step E the protecting group on compound (8) is removed under conditions well known in the art that may vary depending upon the particular protecting group utilized to provide the desired deprotected compound 5 described by structure (9).

For example the appropriately substituted compound (8) wherein Pg is an acid sensitive protecting group such as tert-butyldimethylsilyl group, is dissolved in a suitable 10 solvent mixture, such as methanol and water in about a one to one ratio and then treated with 6N hydrochloric acid until the pff of the reaction is about 2. The reaction is allowed to stir for about 2 to 6 hours and is then concentrated under vacuum to provide the desired 15 deprotected compound (9).

More specifically, the compounds of the formulas (I) and (II) wherein A is an appropriately substituted 5-5 bicyclic ring system, Xi and X3 are hydrogen, and X2 or X is 20 CH2NH2r C02H, CONH2 or CH2OH can be prepared as described in Scheme IV. All other substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. -28-Scheme IV For example, in Scheme IV, step A the cyano derivative described by structure (10) [prepared by nucleophilic substitution of the appropriately substituted derivative of compound (3) with potassium cyanide as described generally in Scheme II, step B] is reduced to the appropriately substituted aminomethyl compound described by structure (11).

For example, an appropriately substituted cyano compound described by structure (10) is dissolved in a suitable, solvent, such as tetrahydrofuran and treated with an excess of a suitable reducing anient, such as 2M aluminum hydride in tetrahydrofuran. The re%cticn is refluxed for 2 10 to 6 hours. Excess reducing agent Is carefully decomposed by treatment with acetone and then acidified to pH 7. The mixture is then filtered and the filtrate is concentrated under vacuum. The residue is purified by techniques well known to one skilled in the art. For example,, the residue 15 is purified by flash chromatography on silica gel with methylene chloride:methanol (17:3) as eluent to provide the aminomethyl compound described by structure (11).

In Scheme IV, step B the appropriately substituted 20 cyano compound described by structure (10) is hydrolyzed to the appropriately substituted amide described by structure (12).

For example, an appropriately substituted cyano 25 compound described by structure (10) is dissolved in a suitable solvent, such as methanol and treated with an equivalent of a suitable base, such as potassium hydroxide. The reaction is heated at reflux for 1 to 5 hours and then concentrated under vacuum. The residue is then purified by 30 techniques well known in the art. For example the residue can be purified by flash chromatography on silica gel utilizing a suitable eluent, such as methylene chloride:methanol to provide the purified amide (12).

In Scheme IV, optional step C the appropriately substituted cyano compound described by structure (12) is WO 95/03304 PCT/DS94/07147 hydrolyzed to the appropriately substituted carboxylic acid described by structure (13).

For example, an appropriately substituted cyano 5 compound described by structure (10) is dissolved in a suitable organic solvent, such as tetrahydrofuran. An excess of a suitable base, such as potassium hydroxide is added and the reaction is heated at reflux for approximately 6 hours. After cooling, the reaction is 10 neutralized with a suitable acid, such as 6N hydrochloric acid and the product purified by techniques well known to one skilled in the art. For example, the product can be isolated by ion exchange chromatography to provide the carboxylic acid described by structure (13).

In Scheme IV, step D the appropriately substituted carboxylic acid described by structure (13) is reduced to the appropriately substituted alcohol described by structure (14).

For example, an appropriately substituted carboxylic acid described by structure (13) is dissolved in a suitable organic solvent, such as tetrahydrofuran. An excess of a suitable reducing agent, such as 2M lithium aluminum 25 hydride in tetrahydrofuran is added dropwise to the reaction. The reaction is heated at reflux for 2 to 6 hours. After cooling, excess reducing agent is decomposed by treatment with acetone followed by dilute hydrochloric acid to adjust to pH 7. The mixture is then filtered and 30 the filtrate is concentrated under vacuum. The residue is then purified by techniques well known to one skilled in the art. For example, the residue can be purified by flash chromatography using methylene chloride:methanol (17:3) as the eluent to provide the hydroxymethyl derivative 35 described by structure (14).

WO 95/03304 PCT/US94/07147 The compounds of the formulas (I) and (II) wherein A is an appropriately substituted 5-5 bicyclic ring system, Xi and X3 are hydrogen, and X or X2 is NH2 can be prepared as described in Scheme V. All other substituents, unless 5 otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art.

Scheme V NH2 16 Q = CH2 or oxygen In Scheme V, the appropriately substituted azide [prepared by nucleophilic substitution of sodium azide on compound (3) as described generally in Scheme II, step B] 25 described by structure (15) is reduced to the appropriately substituted primary amine described by structure (16).

For example, an appropriately substituted azide (15) is dissolved in a suitable organic solvent, such as 30 tetrahydrofuran and treated with an excess of a suitable reducing agent, such as 2M lithium aluminum hydride in tetrahydrofuran. The reaction .s heated at reflux for 2 to 6 hours. After cooling, the excess reducing agent is decomposed with water, the mixture is filtered and the 35 filtrate is concentrated under vacuum. The residue is then purified by techniques well known to one skilled in the art. For example, the residue is purified by flash PCT /US94/07147 chromatography using silica gel and a suitable organic eluent, such as methylene chloride methanol (17:3) to provide the appropriately substituted primary amine described by structure (16).

The compounds of formula (III) can be prepared following the procedure described by Klessing and Chatterjee in U.S. Patent No. 4,479,951, October 30, 1984 and by Klessing, K. in U.S. Patent No. 4,535,158, August 10 13, 1985 the disclosure of which are hereby incorporated by reference.

The relative configurations encompassed by the stereoisomers of formulas (I), (II) and (III) are readily 15 prepared by one skilled in the art. In addition the enantiomers of formulas (I), (II) and (III) can be resolved utilizing techniques well knowr in the art of chemistry such as crystallization techniques described by Jacques, J. et al. "Enantiomers, Racemates, and Resolutions", John 20 Wiley and Sons, Inc., 1981 or by chiral column chromatography.

The following examples present typical syntheses as described by Schemes I, II, III, IV and V. These examples 25 are understood to be illustrative only and are not intended to limit the scope of the invention in any way. As used in the following examples, the following terms have the meanings indicated: "eq." refers to equivalents, "g" refers to grams, "nig" refers to milligrams, "mmol" refers 30 to millimoles, MmL" refers to milliliters, "°CM refers to degrees Celsius, "5" refers to ppm downfield from tetramethylsilane, "Pg" refers to a protecting group, "TLC" refers to thin layer chromatography and "Rf" refers to retention factor. -33-Example 1 NH2 OH Preparation of the final product, (+)-Exo-2-adenvl-endo-6-hvdroxvbicvclor3>3/01 octane dihydrochloride.

Scheme III, step A; Preparation of (+)-Diendo-2,6-dihvdroxvbicvclo[3.3/01octane« Dissolve (+)-diendo-2,6-diacetoxybicyclo[3,3/0]octane (1.5 g» 6.6 mmol) in methanol (60 mL) and add potassium -( , ' hydroxide (0.53 q, 13.2ramol). Stir the reaction for 1 20 hours at room temperature. Concentrate the reaction under vacuum and dissolve the- residue in methylene chloride. Filter the solution and dilute with methylene chloride/ethyl acetate (lsl). Pass the solution through a plug of silica gel and concentrate the collected eluent 25 under vacuum to provide the title compound (730 mg). 34- Scheme III, step B; Preparation of (+)-Diendo-6-t-butvldimethvlsilvloxv-2-hydroxvbicvclo[3,3,01octane.

Dissolve (+)-diendo-2,6-dihydroxybicyclo[3,3,0]octane (0.73 g, 5.1 mmol) in methylene chloride (50 mL) and add tert-butyldimethylsilyl chloride (0.77 g, 5.1 mmol)/ 4-dimethylaminopyridine (10 mg) and triethylamine (0.52 g, .1 mmol). Stir the reaction overnight. Wash the reaction 10 with water, brine, dry over anhydrous sodium sulfate, filter and concentrate under vacuum to provide an oil. Purify the crude oil by flash chromatography (hexane/ethyl acetate, 3:2, silica gel) to provide the title compound (1.07 g).

Scheme III, steps C and D; Preparation of (+)-Exo-2-adenvl-endo-6-t- butvldimethvlsilvloxvbicvclo[3,3,0]octane.

Dissolve (+)-Diendo-6-t-butyldimethylsilyloxy-2-20 hydroxybicyclo[3,3,0]octane (0.9 g, 3.5 mmol) in methylene chloride (30 mL). Add methanesulfonyl chloride (0.48 g, 4.2 mmol), triethylamine (0.42 g, 4.2 mmol) and stir for one hour. Rinse the reaction with water, brine, dry over anhydrous sodium sulfate, filter and concentrate to yield the mesylate as a yellow oil. This mesylate is then immediately added to a reaction bomb containing a solution of sodium adenide in dimethylformamide, [prepared by treating adenine (1.43 g, 10.5 mmol) in dimethylformamide (30 mL) with sodium hydride (0.42 g of a 60% dispersion, 30 10.5 mmol) and stirring for 1.25 hours at room temperature]. Seal the reaction bomb and heat at 150°C overnight. Then transfer the reaction mixture to a round bottom flask and concentrate under vacuum. Dissolve the residue in methylene chloride, rinse with water, brine, dry 35 over anhydrous sodium sulfate, filter and concentrate under vacuum. Purify the residue by flash chromatography (methylene chloride/ethanol, silica gel) to provide the title compound (260 mg).

Scheme III, step E; Dissolve ( + )-Exo-2-ade. yl-endo-6-t-5 butyldimethylsilyloxybicyclo[3,3,0]octane (240 mg, 0.6 minol) in methanol (50 mL) and water (50 mL). Add 6N hydrochloric acid until the pH = 2. Stir the reaction for 3 hours at room temperature and then concentrate under vacuum to provide the title compound (210 mg); NMR (DMSO-10 d£) 6 8.7 (S, 1H), 8.55 (Sr IB), 4.55 (q, 1H), 4.0 (q, 1H), 2.8 (m, 1H), 2.7 (ra, 1H), 2.15 (m, 2H), 1.95 (m, 1H), 1.8-1.45 (m, 6H).

Example 2 NH2 CN Preparation of (+ )-Diexo-"2-adenyl-6-25 cvanobicvclo f 3,3,0 3 octane.

Scheme II, step A; Dissolve (+)-Exo-2-adenyl-endo-6~ hydroxybicyclo[3,3#0]octane (0.7 mmol) in methylene chloride (15 mL) and tetrahydrofuran (9 mL). Add excess methanesulfonyl chloride and triethylamine and stir for 30 30 minutes. Add water (50 mL) and separate the layers.

Extract the aqueous phase with methylene chloride (50 mL), combine the organic phases and dry over anhydrous sodium sulfate. Filter and concentrate to provide (+)-exo-2-adenyl-endo-6-methanesulf oxybicyclo[3,3,0]octane.

Scheme II, step B; Dissolve (+)-exo-2-adenyl-endo-6-methanerjlfoxybicyclo[3,3,0]octane (0.6 mmol) and potassium cyanide (1.2 mmol) in dimethylsulfoxide. Heat the reaction at 75°C for 6 hours and then concentrate under vacuum. Purify the residue by dissolving it in a mixture of methylene chloride methanol (9:1) and then passing the 5 solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Preparation of(+)-Diexo-2-adenvl-bicvclo[3,3,01octane-6-thiol.

Scheme II, step B? Dissolve (+)-exo-2-adenyl-endo-6- methanesulfoxybicyclo[3-,3,0]octane (0.6 mmol, prepared in example 2) and sodium hydrogensulfide (1.2 mmol) in ethanol. Reflux the reaction for three hours and then concentrate under vacuum. Purify the residue by dissolving it in a mixture of methylene chloride:methanol (9:1) and then pass the solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Example 3 NH2 SH y.

Example 4 NH2 sch3 Preparation of(+)-Diexo-2-adenvl-6-methvlmercaptobicvclo f 3.3,01octane.

Scheme II, step B? Combine (+)-exo-2-adenyl-endo-6-15 methanesulfoxybicyclo[3,3,0]octane (0.6 mmol, prepared in example 2) and potassium hydroxide (1.2 mmol) in methanol. Bubble in methyl mercaptan until the solution is saturated and then reflux for three hours. Concentrate the reaction under vacuum. Purify the residue by dissolving it in a 20 mixture of methylene chloridemethanol (9:1) and then pass the solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Example 5 NH2 nhch3 preparation of(+)-Diexo-2-adenyl-6-methvlaminobicvclo[3,3,0]octane.

Scheme II, step B; Dissolve (+)-exo-2-adenyl-endo-6-methanesulfoxybicyclo[3,3,0]octane (0.6 mmol, prepared in example 2) and methylamine (1.2 mmol) in ethanol. Reflux the reaction for three hours and then concentrate under vacuum.ePurify the residue by dissolving it in a mixture of methylene chloride methanol (9:1) and then pass the solution through a silica gel plug. Concentrate the 20 filtrate under vacuum to provide the title compound.

Preparation of(+)-Diexo-2-adenvl-6-dimethylaminobicvclo[3,3,01 octane.

Scheme II, step B; Dissolve lR,3S-cis-l-(9-adenyl)-3-methanesulfoxycyclopentane (0.6 mmol, prepared in example 2) and dimethylamine (1.2 mmol) in ethanol. Reflux the reaction for three hours and then concentrate under vacuum.

Example 6 NH2 N(CH3)2 Purify the residue by dissolving it in a mixture of methylene chloridesmethanol (9:1) and then pass the solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Example 7 NH2 Preparation of (+)-Diexo-2-adenvl-6-aminomethvlbicvclof 3,3.0loctane Scheme IV, optional step A; Dissolve (+)-Diexo-2-adenyl-6-cyanobicyclo[3,3,0]octane (prepared in example 2) in 2(1 tetrahydrofuran and add excess 2M lithium aluminum hydride in tetrahydrofuran dropw-ise. Reflux for two to six hours. Decompose the excess lithium aluminum hydride, filter and concentrate under vacuum. Purify the residue by flash chromatography (silica gel) using methylene 25 chloridesmethanol (17:3) as the eluent to provide the title compound.

Example 8 NH2 Preparation of (+)-Diexo-2-adenyl-bicvclo[3,3.01octane-6-carboxvlic acid.

Scheme IV, optional step C; Dissolve (+)-Diexo-2-adenyl-6-cyanobicyclo[3,3,0]octane (prepared in example 2) in tetrahydrofuran and add excess potassium hydroxide. Reflux for approximately 6 hours. Neutralize the reaction with 6N hydrochloric acid and purify by ionexchange chromatography to provide the title compound.

Example 8b NH2 Preparation of (+)-Diexo-2-adenvl-bicvclof3,3,01octane-6-carboxamide.

Scheme IV, optional step B? Dissolve (+)-Diexo-2-adenyl-6 15 cyanobicyclo[3,3,0]octane (1 mmol, prepared in example 2) in methanol and treat with potassium hydroxide (1 mmol). Heat the reaction at reflux for 2 hours. After cooling concentrate under vacuum and purify the residue by flash chromatography (methylene chloride/methanol, 17:3, silica 2^ gel) to provide the title compound.

Example 9 NH2 Preparation of (+l-Diexo-2-adenvl-6-hvdroxvmethvlbicvclo f 3.3,01octane.

Scheme IV, optional step D; Dissolve (+)-Diexo-2-adenyl-35 bicyclo[3,3,0]octane-6-carboxylic acid (prepared in example 8) in tetrahydrofuran and add excess 2M lithium aluminum hydride in tetrahydrofuran dropwise. Reflux for two to six WO 95/03304 PCT/US94/07147 hour s. Decompose the excess lithium aluminum hydride, filter, concentrate under vacuum and purify in a manner analogous to example 9 to provide the title compound.

\ PCT/US94/07J47 Example 10 NH2 Preparation of (+)-Diexo-2-adenvl-6-azidobicvclof 3,3>01octane.

Scheme I, step B; Dissolve (+)-exo-2-adenyl-endo-6-methanesulfoxybicyclo[3,3,0]octane (0.6 mmol, prepared in 15 example 2) and lithium azide (60 mg, 1.2 mmol) in ethanol (10 mL). Stir overnight at room temperature and then reflux for three hours. Concentrate the reaction under vacuum and purify the residue I dissolving it in a mixture of methylene chloridemethanol (9:1) and then pass the 20 solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Example 11 nh2 vO & nh2 Preparation of (+)-Diexo-2-adenvl-6-aminobicvclot3.3»0loctane dihydrochloride.

Scheme V; Dissolve (+)-Diexo-2-adenyl-6-azidobicyclot3,3,0loctane (prepared in example 10) in tetrahydrofuran and add excess 2M lithium aluminum hydride in tetrahydrofuran dropwise. Reflux for two to six hours. Decompose the excess lithium aluminum hydride, filter and concentrate under vacuum. Purify the residue by dissolving 20 it in a mixture of methylene chloride:methanol (9:1) and then pass the solution through a silica gel plug. Concentrate the filtrate under vacuum to provide the title compound.

Example 12 NH2 nh2 (A) I (B) OH Preparation of (+)-Exo-5-(6-amino-purin-9vl)-octahvdro-pentalene-diendo-1,6-diol (A) and (+)-Exo-3-(6-amino-purin-9vl)-octahvdro-pentalene-diendo-2,5-diol (Bl.

Add cis-endo-8-hydroxy bicyclo[3.3.0]octane-endo-2,3-oxirane (760 mg, 5.4 mmol, prepared according to Shihusaki, M. et al. Tet. Lett. 433, 1979) to a reaction bomb ,, i containing;^ solution of sodium adenide in dimethylformamide, [prepared by treating adenine with an 20 equivalent of sodium hydride in dimethylformamide] and stir at room temperature for 45 minutes. Then seal the bomb,and heat overnight at 150°C to 155°C. Concentrate the reaction under vacuum and purify the residue by flash chromatography on silica gel (methylene chloride/methanol, 9:1) to provide 25 (A) (180 mg) an* (B) (240 mg).

Example 13 NH2 H 6 H Preparation of (±)-Exo-5-(6-amino-purin-9-vl)-cis-decahvdro-naphthalene-endo-l-ol.

Scheme III; In an analogous manner to Example 1 the 15 title compound is prepared from (+)-diendo-l,5-diacetoxydecalin.

Preparation of (±)-Exo-5-(6-aroino-purln-9-vl)-trans-decahvdro-naphthalene-endo-l-ol.

Scheme III; In an analogous manner to Example 1 the title compound is prepared from Trans-l,5-diacetoxy-cis-decalin.

Example 14 NH2 H6 H Example 15 269335 nh2 Preparation of f 3S»6R1-6-(6-Amino-purin-9-vl)-hexahvdro-furo-f 3.2-b1-furan-3-carbonitrile.

Scheme II, step B; In an analogous manner to Example 2 the title compound is prepared from the methanesulfonate 15 derivative of 6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

Preparation of f3S.6Rl-6-(6-Amino-purin-9-vl)-hexahvdro-furo[3,2-b1-furan-3-thiol.

Scheme II, step B; In an analogous manner to Example 3 the title compound is prepared from the methanesulfonate derivative of 6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

Example 16 nh2 -48-Examplen nh2 Co 269335 i H Sch3 Preparation of f3R. 6S1-9-(6-Methylsulfanvl-hexahvdro-furof 3.2-b1-furan-3-vl)-9H-Purin-6-vlamlne.

Scheme II/ atep B; In an analogous manner to Example 4 the title compound is prepared from the methanesulfonate derivative of 6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

Example 18 nh2 w h i h nhch3 Preparation of f3R, 6Sl-9-(6-Methvlaunino-hexahvdro-furo[3,2-b1-furan-3-vl)-9H-pur in-6-vlamine.

Scheme II, step B; In an analogous manner to Example 5 the title compound is prepared from the methanesulfonate derivative of 6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

N.Z. PATEN 1" OFFICE - 5 NOV 1997 RECEIVER ~ 269 33 5 -49-Examole 19 nh2 <X> i h n(ch3)2 Preparation of f3R. 6S1-9-(6-Dimethvlamino-hexahvdro-furof 3.2-b 1 -furan-3-vl) "9H-our in-6-vlamine.

Scheme II, step B; In an analogous manner to Example 6 the title compound is prepared from the methanesulfonate derivative of 6-(6-araino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

Example 20 nh2 h , h ch2nh2 Preparation of f3R, 6S1-9-(6-Aminoemethvl-hexahvdro-furof 3.2-b1-furan-3-vl1-9H-purin-6-ylamine.

Scheme IV, optional step A; In an analogous manner to Example 7 the title compound is prepared from the product prepared in example 15.

N.Z. PATENT OFFICE 2 0 OCT isitf RECEIVE) Example 21 269335 nh2 Preparation of f3S. 6R1-6-( 6-Amino-Purin-9-vH-hexahvdro-furo- [3,2-b1-furan-3-carboxvlic acid.

Scheme IV, optional step C; In an analogous manner to 15 Example 8 the title compound is prepared from the product prepared in example 15.

Preparation of f3S> 6Rl-f6-(6-Amino-purin-9-vl)-hexahvdro-furo- f 3 > 2-b1furan-3-v11-methanol.

Scheme IV, optional step D; In an analogous manner to Example 9 the title compound is prepared from the product prepared in example 21.

Example 22 nh2 N.Z. PATENT OFFICE a 0 ocr wa/ -51- ■ Example 23 NH2 269335 Preparation o£ f3S. 6Rl-6-(6-Amlno-Purin-9-vl)-hexahvdro- £uro- f3r2-b1£uran-3-carboxvlic acid amide.

Scheme IV, optional step B; In an analogous manner to 15 Example 8b the title compound is prepared from the product prepared in example 15.

Preparation of T3R, 6S1-9-(6-a2ido-hexahvdro-furof3.2-blfuran-3-vl)-9H-purin-6-vlamine.

Scheme II, step B; In an analogous manner to Example 10 the title compound is prepared from the methanesulfonate derivative of 6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol.

Example 2.4 nh2 I N .Z. PATENT office a 0 ucr w RECEIVED Examole 25 NH2 H NH2 Preparation of f3R, 6Sl-9-(6-Amino-hexahvdro-furof3,2-b1furan-3vl)-9H-ourin-6-vlamine.

Scheme V; In an analogous manner to Example 11 the title compound is prepared from the product prepared in 15 example 24.

It is to be noted that the following more specific compounds of formula (I) are readily prepared by applying the foregoing described techniques and procedures and by applying known prior art principles to achieve the 5 necessary modifications: Z, formula (I) wherein Y is -N-, Zi is NH2* Z2 is H, and A is selected from the group consisting of; "lining CO- *2 X3 x2 x3 X2 *2 i £ x3 X2 x3 x2 x3 x2 wherein Xi, X2 and X3 are each independently hydrogen, OH, N3, NH2, N(R)2f NHRf CNr CH2NH2, CONH2, C02H, CH2OH or SH wherein R is CX'CA alkyl with the proviso that at least one of Xi, X2 or X3 is other than hydrogen.

In addition it is to be noted that the following more specific compounds of formula (II) are readily prepared by applying the foregoing described techniques and procedures and by applying known prior art principles to achieve the necessary modifications: z, formula (II) wherein Y is -N-, Zi is NH2» Z2 is H, and A is selected from the group consisting of; wherein X is N3, NH2, N(R)2, NHR, CN, CH2NH2, CONH2, C02H, CH2OH, SH wherein R is Cj-C4 alkyl.

The present invention further provides a method of inhibiting TNF-o activity in a patient in need thereof comprising administering to said patient an antiinflammatory amount of a compound of formulas (I), (II) or (III). The present invention further provides a method of treating a patient suffering from certain autoimmune or other diseases for which elevated activity of TNF-a is implicated as a contributing factor in the progression of the disease comprising administering to said patient a compound of formulas (I), (II) or (III).

As used herein, the term "patient" refers to a warmblooded animal such as a mammal which is suffering from, or is in danger of suffering from, an acute or chronic 5 inflammation, cellular injury or cell death associated with an immunological based disease. It is understood that humans, mice and rats are included within the scope of the term "patient".

Administration of a compound of formulas (I), (II) or (III) to a patient results in a selective antiinflammatory effect in the patient. More specifically, administration of a compound of formulas (I), (II) or (III) to a patient results in inhibition of TNF-o activity in the patient which 15 selectively inhibits TNF-a-mediated inflammatory events. In other words, by treatment of a patient with a compound of formulas (I)» (II) or (III), the TNF-a-mediated inflammatory response and subsequent inhibition of other cytokines associated with various diseases is inhibited or suppressed 20 over that present in the absence of treatment.

A patient is in need of treatment with an agent which inhibits TNF-a activity, such as a compound of formulas (I), (II) or (III), where the patient is suffering from certain 25 autoimmune or other diseases for which elevated activity of TNF-a is implicated as a contributing factor in the progression of the disease. The term "autoimmune disease" refers to those disease states and conditions wherein the immune response of the patient is directed against the 30 patient's own constituents resulting in an undesirable and often terribly debilitating condition.

Patients suffering from autoimmune diseases such as septic shock, ARDS, inflammatory bowel disease including 35 ulcerative colitis and Chrohn's disease, rheumatoid arthritis, fever/cachexia (wasting syndrome)/Myobacterium tuberculosis infections in patients with AIDS, diabetes WO 95/03304 PCT/US94/07147 mellitus type I, Kawasaki disease, multiple sclerosis,familial Mediterranean fever, toxic shock syndrome are in need of treatment with a selective antiinflammatory agent such as a compound of formulas (I), (II) or (III). In 5 addition, patients suffering from bacterial meningitis, vascular injury/atherosclerosis, leprosy, anemia of chronic disease, ultraviolet radiation, Helicobacter pylori gastritis/ulcer disease, paracoccidioidomycosis, septic melioidosis, heart failure, chronic fatigue syndrome, 10 allograft rejection, Graft-versus-host disease, Schistosomiasis are also in need of treatment with a selective antiinflammatory agent such as a compound of formulas (I), (II) or (III). As such, treatment of patients suffering from these diseases by administration of a 15 compound of formulas (I), (II) or (III) will be particularly effective in preventing further deterioration or worsening of the patient's condition. Treatment of a patient at an early stage of an autoimmune disease would be particularly effective in preventing further deterioration of the disease 20 state into a more serious condition.

Patients suffering from septic shock, ARDS, AIDS, fever/cachexia/Myobacterium tuberculosis infection associated with AIDS, inflammatory bowel disease including ulcerative 25 colitis and Chrohn's disease, bacterial meningitis, and rheumatoid arthritis are particularly good candidates for treatment with a compound of formulas (I), (II) or (III).

Based on standard clinical and laboratory tests and 30 procedures, an attending diagnostician, as a person skilled in the art, can readily identify those patients who are in need of treatment with a selective antiinflammatory agent such as a compound of formulas (I), (II) or (III).

An effective antiinflammatory amount of a compound of formulas (I), (II) or (III) is that amount which is effective, upon single or multiple dose administration to a patient, in providing an antiinflammatory effect or, more particularly, an inhibition of TNF-a activity. An antiinflammatory effect refers to the slowing, interrupting, inhibiting or preventing the further expression of TNF-a-5 mediated inflammatory effects.

An effective antiinflammatory amount of a compound of formulas (1), (II) or (III) can be readily determined by the attending diagnostician, as one skilled in the art# by the 10 use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size# age, and general health; the 15 specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use 20 of concomitant medication; and other relevant circumstances.

An effective antiinflammatory amount of a compound of formulas (I), (II) or (III) is expected to vary from about 0.1 milligram per kilogram of body weight per day 25 (mg/kg/day) to about 500 mg/kg/day. Preferred amounts are expected to vary from about 1 to about 50 mg/kg/day.

In effecting treatment of a patient, a compound of formulas (I), (II) or (III) can be administered in any form 30 or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, compounds of formulas (I), (II) or (III) can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally# intranasally, rectally, and 35 the like. Oral administration and intravenous administration are generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected the disease state to be treated, the stage of the disease, and other relevant circumstances.

The compounds can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the 10 solubility and chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. The compounds of the invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically 15 acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.

In another embodiment, the present invention provides 20 compositions comprising a compound of formulas (I), (II) or (III) in admixture or otherwise in association with one or more inert carriers. These compositions are useful, for example, as assay standards, as convenient means of making bulk shipments, or as pharmaceutical compositions. An 25 assayable amount of a compound of formulas (I), (II) or (III) is an amount which is readily measurable by standard assay procedures and techniques as are well known and appreciated by those skilled in the art. Assayable amounts of a compound of formulas (I), (II) or (III) will generally 30 vary from about 0.001% to about 75% of the composition by weight. Inert carriers can be any material which does not degrade or otherwise covalently react with a compound of formulas (I), (II) or (III). Examples of suitable inert carriers are water; aqueous buffers, such as those which 35 are generally useful in High Performance Liquid Chromatography (HPLC) analysis; organic solvents, such as acetonitrile, ethyl acetate, hexane and the like; and pharmaceutically acceptable carriers or excipients.

More particularly, the present invention provides 5 pharmaceutical compositions comprising an effective immunosuppressive amount of a compound of formula (I), (II) or (III) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

The pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known 15 in the art. The pharmaceutical composition may be adapted for oral or parenteral use, including topical use, and may be administered to the patient in the form of tablets, capsules, suppositories, solution, suspensions, or the like.

The compounds of the.present invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of 25 oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of the compound of the 30 invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the compound present in compositions is such that a suitable dosage will be obtained. Preferred compositions 35 and preparations according to the present invention are prepared so that an oral dosage unit form contains between 5.0-300 milligrams of a compound of the invention.

The tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth 5 or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be 10 added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain 15 other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the present compounds, sucrose as a sweetening agent and 20 certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

Por the purpose of parenteral therapeutic administration, including topical administration, the compounds of the present invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of the invention, but 30 may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the inventive compound present in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a 35 parenteral dosage unit contains between 5.0 to 100 milligrams of the compound of the invention.

The solutions or suspensions may also include the one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other 5 synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity 10 such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

As with any group of structurally related compounds 15 which possesses a particular generic utility, certain groups and configurations are preferred for compounds of formula (I) in their end-use application. Compounds of the formula (I) wherein Y is nitrogen are generally preferred. Compounds of the formula (I) wherein Z2 is NH2 and Zi is 20 hydrogen are generally preferred.

The following specific compounds of formula (I) are especially preferred: 1) (+)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane dihydrochloride, 2) (±)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane, 3) (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1, 6-diol, 4) (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-1, 6-diol dihydrochloride, ) (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, 6) (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol dihyrochloride.

Certain groups and configurations are also preferred for compounds of formula (II) in their end-use application. Compounds of the formula (II) wherein Y is nitrogen are generally preferred. Compounds of the formula (II) wherein Z2 is NH2 and Zi is hydrogen are generally preferred.

Certain groups and configurations are also preferred for compounds of formula (III) in their end-use application. Compounds of the formula (III) wherein Y is nitrogen are generally preferred. Compounds of the formula 15 (III) wherein Z2 is NH2 and Zi is hydrogen are generally preferred.

The following specific compounds of formula (III) are especially preferred: 1) [3Sr 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol; 2) [3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-25 b]furan-3-ol dihydrochloride; 3) [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol; 4) [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol dihydrochloride.

The following studies illustrate the utility of the compounds of formulas (I), (II) or (III). These studies 35 are understood to be illustrative only and are not intended to limit the scope of the invention in any way. As used herein the following terms have the indicated meanings: "uM" refers to micromolar concentration; "Units" refers to the internationally accepted measurement of protein; "S.D." refers to standard deviation; "nmol" refers to nanomoles; "ng" refers to nanograms.

In Vitro Activity Utilizing an in vitro cellular immunology-based assay which uses human peripheral blood and subsequent 10 purification of monocyte-derived macrophages (according to the method of Edwards et al. J. Cellular Biochemistry 1993, 19E» 35), (+)-exo-2-adenyl-endo-6- hydroxybicyclo[3,3,0]octane dihydrochloride showed activity in proinflammatory cytokine inhibition. Monocyte-derived 15 macrophages stimulated with bacterial lipopolysaccharide (LPS) produce high levels of TNF-a (25.8+4.2 ng/mL) during 18 hours of culture. (+)-Exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane dihydrochloride was effective at inhibiting TNF-a levels in a dose response fashion (100 20 uH - 0.1 uM) with an IC50 value of 0.143+0.091 yM in comparison to .the positive control compound used in this assay (Pentoxifylline [PTX]; inhibition at 50yM = 73.5%).

In Vivo Activity Utilizing an in vivo immunology-based assay which uses a D-galactosamine animal model of septic shock (according to the method of Parmely et al. European Cytokine Network. vol.3, No.2, page 249, (+)-exo-2-adenyl-endo-6-30 hydroxybicyclo[3,3f0]octane dihydrochloride showed elevated activity in protecting mice against the lethal effects of LPS. Mice treated with the vehicle Hanks Balanced Salt Solution (HBSS) approximately 1 hour before intraperitoneal (i.p.) challenge of D-galactosamine and LPS, succumbed to 35 disease by 18 hours after challenge (e.g. 6 out of 8 mice killed; 25% protection). However, mice treated with ( + )-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane

Claims (30)

WO 95/03304 PCT/US94/07147 -66- dihydrochloride (100 mg/kg i.p., time » -1 hour) were afforded significantly (p < 0.05 by x2 analysis) enhanced protection (0 out of 8 mice killed; 100% protection). Positive-control PTX afforded decreased protection in this 5 model (7 out of 8 mice killed; 12.5% protection). 10 15 20 25 30 35 I M0169R V -67- WHAT IS CLAIMED IS:

1. A -compound of the focmula 10 15 where in ¥ is nitrogen or CH; Zj and Z2 are each independently hydrogen, halogen or NH2; and A is selected from the group consisting of: X 20 25 wherein Xi, X2 and X3 are each independently hydrogen, OH, 30 n3, NH2, N(R)2r NHR, CN, CH2NH2, CONH2, C02H, CH2OH, SH or SR; wherein R is CL-C4 alkyl; and the pharmaceutically. acceptable salts thereof; with the proviso that at least one of Xi, X2 or X3 is other 35 than hydrogen, ' : ■ •—\ -y iMCNn?0 SHEET 269 3^ «.> *ia #irt*er pro *iso tlaa^ vitietv U is Tg&ti %% is E or ia *3 X3 is S or OE; X2 is S; then Xi is not CO2H/ and with the further proviso that when Z2 is S; A is CO^Hi „v 13 oth«t t'rvafl. a nai°<3erl' WO 95/03304 PCT/US94/07147 -69- 26 9 33 5

2. A compound of the formula z, ju-> '06 5 10 x wherein 15 Y is nitrogen or CH; Zx and Z2 are each independently hydrogen, halogen or NE2; and X is N3, NH2, N(R)2, NHR, CN, CH2NH2, CONH2, C02H, CH2'OH, SH or SR; 20 wherein R is Cj-Cj alkyl; and the pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 wherein Y is nitrogen.

4. The compound according to claim 3 wherein Z2 is hydrogen.

5. The compound according to claim 4 wherein Zi is NH2.

6. Thecompound according to claim 1 wherein A is an octahydropentalene.

7. The compound according to claim 6 wherein X2 is n3. 25 30 35 nitrogen.

8. The compound according to claim 2 wh PCT/US94/07147 2693 3 5

9. The compound according to claim 8 wherein Z2 is hydrogen. 5

10. The compound according to claim 9 wherein Zi is NH2.

11. The compound according to claim 2 wherein X is N3. 10

12. The compound according to claim 11 wherein ¥ is nitrogen.

13. The compound according to claim 12 wherein Z2 is hydrogen. 15

14. The compound of claim 1 wherein the compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane dihydrochloride. 20

15. The compound of claim 1 wherein the compound is (+)-exo-5- (6-amino-pur in79-yl) -octahydropentalene-diendo-1,6-diol.

16. The compound of claim 1 wherein the compound is 25 (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol. 35 N.Z. PATENT OFFinP WO 95/03304 -70- 2 0 OCT 1937 . -71- 2 6 9 3 3 5

17. use of a compound according to claim 1 for the preparation of a medicament for the inhibition of Tumor Necrosis Factor alpha.

18. Use of a compound according to claim 1 for the preparation of a medicament for the treatment of septic shock.

19. Use of a compound according to claim 1 for the preparation of a medicament for inhibiting Tumor Necrosis Factor alpha in a patient in need suffering from septic shock comprising administering to the patient an amount* of a compound according to claim 1.

20. Use of a compound according to claim 2 for the preparation of a medicament for the inhibition of Tumor Necrosis Factor alpha.

21. Use of a compound according to claim 2 for the preparation of a medicament for the treatment of septic shock.

22. Use of a compound according to claim 2 for the preparation of a medicament for inhibiting Tumor Necrosis Factor alpha in a patient in need suffering from septic shock comprising administering to the patient an amount of a compound according to claim2.

23. Use of a compound for the preparation of a medicament for inhibiting Tumor Necrosis Factor alpha in a patient suffering from septic shock comprising administering to the patient an amount of a compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclot3,3,0]octane dihydrochloride, (£)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0]octane, (+)-exo-5-(6-amino-purin-9-yl)-octahydr open t?.lene-diendo-l,6-diol, (+ )-exo-5-(6-amino-pur in-9-yl)-octahydropentalene-diendo-1,6- diol dihydrochloride, (f>—nmi nn-pniri )~_ octahydropentalene-diendo-2,4-diol, (+)-exo __ N.Z PATENT nrcir-tT ■ t fi■' jim>-n1 "-'E I-1 ( 2 0 OCT 1997 1 RECFlVPn -72- purin-9-yl)-octahydropentalene-diendo-2,4-t^<^ ^335 dihyrochloride, (3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol, (3S, 6R]-6-(6-amino-purin-9-yl )-hexahydro-furo[3,2-b]furan-3-ol dihydrochloride, [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo [3,2-b]furan-3-ol, or [ 3R, 6R]-6-( 6-amino-pur i'n-9-yl )-hexahydro-f uro[ 3V2-b] furan-3-ol dihydrochloride.

24. Use of a compound for the preparation of a medicament for the inhibitio-i of Tumor Necrosis Factor alpha, wherein the compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclof3,3,0]octane dihydrochloride, (+)-exo-2-adenyl-endo-6-hydroxybicyclo[3,3,0 Joctane, (+)-exo-5-{6-amino-purin-9-yl)-octahydropentalene-diendo-1,6-diol, (+)-exo-5-(6-amino-pur in-9-yl)-octahydropentalene-diendo-1,6-diol dihydrochloride, (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, (+)-exo-3-(6-amino-purin-9-yl)-octahydropentalene-diendo-2,4-diol dihyrochloride, [3S, 6R]-6-{6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol, [3S, 6R]-6'*(6-amino-purin-9-yl)-\ hexahydro-£uro[3,2-b]furan-3-ol dihydrochloride, [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo{3,2-b]furan-3-ol, or [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]furan-3-ol dihydrochloride. 9

25. Use of a compound for the preparation of a medicament for the treatment of septic shock, wherein the compound is (+)-exo-2-adenyl-endo-6-hydroxybicyclot3,3,0Joctane dihydrochloride, (+)-exo-2-adenyl-endo-6-hydroxybicyclo(3,3,0 Joctane, (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-diendo-l,6-diol, (+)-exo-5-(6-amino-purin-9-yl)-octahydropentalene-aiendo-l,6-diol dihydrochloride, {+)-exo-3-(6-smino-purin-9-yl)-octahydropentalene-diendo-2,4-diol, (+)-exo-3-(6-amino-pur in-9-yl )-octahydropentalene-diendo-2,4-diol dihyrochloride, [3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo(3,2-b]furan-3-ol, (3S, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[ 3,2-b] furan-3-ol dihydrochlorid]Sj_J_3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-furo[3,2-b]fur; [3R, 6R]-6-(6-amino-purin-9-yl)-hexahydro-fur< 3-ol dihydrochloride. -73- 2®9 33 5

26. A pharmaceutical composition comprising an effective immunosuppressive amount of a compound as claimed in any one of claims 1 to 16 in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

2 7. A compound as defined in claim 1 of the general formula defined therein and the pharmaceutically acceptable salts thereof substantially as herein described with'reference to any example thereof.

28. a compound as defined in claim 2 of the general formula defined therein and the pharmaceutically acceptable salts thereof substantially as herein described with reference to any example thereof.

29. Use as claimed in any one of claims 17 to 25 of a compound substantially as herein described with reference to any example thereof. »

30. A pharmaceutical composition as claimed in claim 26 substantially as herein described with reference to any example thereof. By the authorised agents end of claims N.Z. PATENT nrmr-p